Polymyositis, Dermatomyositis, and Statins: A Review
DOI:
https://doi.org/10.7175/cmi.v12i1.1364Keywords:
Statins, Dermatomyositis, Polymyositis, Autoimmune MyositisAbstract
BACKGROUND: Statins are a well-recognized cause of a variety of skeletal myopathic effects, which generally resolve when discontinuing the treatment. Among autoimmune manifestations associated with statins, there are typical polymyositis (PM) and typical dermatomyositis (DM).
OBJECTIVE: To perform a review on published case reports and case series about statin-associated PM and DM.
METHODS: This literature comprehensive search was conducted mainly on PubMed, but also congress abstracts and university websites were considered. Given the paucity of cases, the search was extended to include articles in all languages with English abstract.
RESULTS: Twenty-eight PM and 30 DM cases have been described with prevalence in female (64%) and senile age. The drugs most frequently involved were atorvastatin and simvastatin. The differential diagnosis should be made among the main myositis subtypes: immuno-mediated necrotizing myopathy (IMNM), inclusion body myositis (IBM), and overlap syndrome with myositis (OM), including anti-synthetase syndrome (ASS).
CONCLUSIONS: Even though the onset of polymyositis or dermatomyositis is a rare phenomenon, it is advisable to consider their presence in patients taking statins and with a non-reversible elevation of creatine phosphokinase.
References
Selva-O’Callaghan A, Alvarado-Cardenas M, Pinal-Fernández I, et al. Statin-induced myalgia and myositis: an update on pathogenesis and clinical recommendations. Expert Rev Clin Immunol 2018; 14: 215-24; https://doi.org/10.1080/1744666X.2018.1440206
Furst DE, Amato AA, Iorga SR, et al. Epidemiology of adult idiopathic inflammatory myopathies in a U.S. managed care plan. Muscle Nerve 2012; 45: 676-83; https://doi.org/10.1002/mus.23302
Kanth R, Shah MS, Flores RM. Statin-associated polymyositis following omeprazole treatment. Clin Med Res 2013; 11: 91-5; https://doi.org/10.3121/cmr.2012.1110
Fauchais AL, Iba Ba J, Maurage P, et al. Polymyositis induced or associated with lipid-lowering drugs: five cases. Rev Med Interne 2004; 25: 294-8; https://doi.org/10.1016/j.revmed.2003.10.013
Wu Y, Lach B, Provias JP, et al. Statin-associated autoimmune myopathies: a pathophysiologic spectrum. Can J Neurol Sci 2014; 41: 638-47; https://doi.org/10.1017/cjn.2014.22
Giordano N, Senesi M, Mattii G, et al. Polymyositis associated with simvastatin. Lancet 1997; 349: 1600-1; https://doi.org/10.1016/S0140-6736(05)61628-5
Riesco-Eizaguirre G, Arpa-Gutierrez FJ, Gutierrez M, et al. Severe polymyositis with simvastatin use. Rev Neurol 2003; 37: 934-6
Takagi A, Shiio Y. Pravastatin-associated polymyositis, a case report. Rinsho Shinkeigaku 2004; 44: 25-7
Folzenlogen D. A case of atorvastatin combined toxic myopathy and inflammatory myositis. J Clin Rheumatol 2001; 7: 340-5; https://doi.org/10.1097/00124743-200110000-00019
Sailler L, Pereira C, Bagheri A, et al. Increased exposure to statins in patients developing chronic muscle diseases: a 2-year retrospective study. Ann Rheum Dis 2008; 67: 614-9; https://doi.org/10.1136/ard.2007.075523
Padala S, Thompson PD. Statins as a possible cause of inflammatory and necrotizing myopathies. Atherosclerosis 2012; 22: 15-21; https://doi.org/10.1016/j.atherosclerosis.2011.11.005
Borges IBP, Silva MG, Misse RG, et al. Lipid-lowering agent-triggered dermatomyositis and polymyositis: a case series and literature review. Rheumatol Int 2018; 38: 293-301; https://doi.org/10.1007/s00296-017-3821-3
Watad A, Soriano A, Vaknine H, et al. Immune mediated myopathy following long-term statin therapy. Isr Med Assoc J 2015; 17: 128-9
Protić D, Baltić S, Stupar NV, et al. A case of myositis with immunological background associated with statin use. Cent Eur J Med 2014; 9: 619-24; https://doi.org/10.2478/s11536-013-0313-z
Horák T, Voháňka S, Tvrdíková, et al. Statin-induced necrotizing autoimmune myopathy. Cesk Slov Neurol N 2017; 80/113: 569-77; https://doi.org/10.14735/amcsnn2017569
Gupta S, Blaivas M, Ike RW, et al. Polymyositis evolving after rhabdomyolysis associated with HMG-CoA reductase inhibitors: a report of two cases. J Clin Rheumatol 2001; 7: 332-5; https://doi.org/10.1097/00124743-200110000-00015
Zaraa IR, Labbène I, Mrabet D, et al. Simvastatin-induced dermatomyositis in an 50-year-old-man. BMJ Case Rep 2011; 2011: bcr0220113832; http://dx.doi.org/10.1136/bcr.02.2011.3832
Komai I, Takemoto M, Yokote K. Atorvastatin-induced dermatomyositis in an 47-year-old woman with Sjögren’s syndrome. Acta Cardiol 2015; 70: 373; https://doi.org/10.1080/AC.70.3.3080648
Rasch A, Schimmer M, Sander CA. Simvastatin-induced dermatomyositis. Hautarzt 2009; 60: 483-9; https://doi.org/10.1007/s00105-008-1637-5
Vasconcelos OM, Campbell WW. Dermatomyositis-like syndrome and HMG-CoA reductase inhibitor (statin) intake. Muscle Nerve 2004; 30: 803-7; https://doi.org/10.1002/mus.20127
Noël B, Cerottini JP, Panizzon RG. Atorvastatin-induced dermatomyositis. Am J Med 2001; 110: 670-1; https://doi.org/10.1016/S0002-9343(01)00711-2
Zuech P, Pauwels C, Dulhoit C, et al. Pravastatin-induced dermatomyositis. Rev Med Interne 2005; 26: 897-902; https://doi.org/10.1016/j.revmed.2005.07.005
Khattak FH, Morris IM, Branford WA. Simvastatin-associated dermatomyositis. Br J Rheumatol 1994; 33: 199; https://doi.org/10.1093/rheumatology/33.2.199
Rodriguez-Garcia JL, Serrano Commino M. Lovastatin-associated dematomyositis. Postgrad Med J 1996; 72: 694; https://doi.org/10.1136/pgmj.72.853.694
Hill C, Zeitz C, Kirkham B. Dermatomyositis with lung involvement in a patient treated with simvastatin. Aust N Z J Med 1995; 25: 745-6; https://doi.org/10.1111/j.1445-5994.1995.tb02870.x
Thual N, Penven K, Chevalier JM, et al. Fluvastatin-induced dermatomyositis. Ann Dermatol Venereol 2005; 132: 996-9
Schalke BB, Achmidt B, Toyka K, et al. Pravastatin-associated inflammatory myopathy. N Engl J Med 1992; 327: 649-50; https://doi.org/10.1056/NEJM199208273270919
Inhoff O, Peitsch WK, Paredes BE, et al. Simvastatin-induced amyopathic dermatomyositis. Br J Dermatol 2009; 161: 206-8; https://doi.org/10.1111/j.1365-2133.2009.09205.x
Cannon CS. Statin-induced rhabdomyolysis and dermatomyositis: a rare combination. JAAPA 2012; 25: 30,32-3; https://doi.org/10.1097/01720610-201208000-00006
Fania L, Didona D, Tonanzi T, et al. Simvastatin-associated dermatomyositis. Dermatol Ther 2017; 30. Epub 2017 Mar 14. https://doi.org/10.1111/dth.12480
Oztas M, Ugurlu S, Aydin O. Atorvastatin-induced dermatomyositis. Rheumatol Int 2017; 37: 1217-9; https://doi.org/10.1007/s00296-017-3658-9
Chemello RML, Benvegnù AM, Dallazem LND, et al. Aggressive and fatal statin-induced dermatomyositis: a case report. Oxf Med Case Reports 2017; 12: 242-5; https://doi.org/10.1093/omcr/omx063
Tihanyi L, Sutô G, Veress G. Necrotising autoimmune myopathy showing dermatomyositis symptoms during persistent statin treatment. Lege Artis Medicinae 2013; 23: 113-6
Spiro J, Butts M. Atorvastatin-induced dermatomyositis: resolution with change in statin? JCR 2018; 24: 406-9; https://doi.org:110.10977/RHU.0000000000000709
Hydzik P, Szpak D. Side effects on the HMG-CoA reductase inhibitors (statins). Lupus erythematosus induced by atorvastatin therapy. Przegl Lek 2011; 68: 495-8
Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975; 292: 344-7; https://doi.org/10.1056/NEJM197502132920706; https://doi.org/10.1056/NEJM197502202920807
Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med 1975; 292: 403-7; https://doi.org/10.1056/NEJM197502132920706; https://doi.org/10.1056/NEJM197502202920807
Hoogendijk JE, Amato AA, Lecky BR, et al. 119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10-12 October 2003, Narden, The Netherlands. Neuromuscul Disord 2004; 14: 337-45; https://doi.org/10.1016/j.nmd.2004.02.006
Lundberg IE, Tjärnlund A, Bottai M, et al. 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Ann Rheum Dis 2017; 76: 1955-64; https://doi.org/10.1136/annrheumdis-2017-211468
Lilleker JB, Vencovsky J, Wang G, et al. The EuroMyositis registry: an international collaborative tool to facilitate myositis research. Ann Rheum Dis 2018; 77: 30-9; https://doi.org/10.1136/annrheumdis-2017-211868
Schmidt J. Current classification and management of inflammatory myopathies. J Neuromuscul Dis 2018; 5: 109-29; https://doi.org/10.3233/JND-180308
Selva-O’Callaghan A, Pinal-Fernández I, Trallero-Araguàs E, et al. Classification and management of adult inflammatory myopathies. Lancet Neurol 2018; 17: 816-28; https://doi.org/10.1016/S1474-4422(18)30254-0
Mariampillai K, Granger B, Amelin D, et al. Development of a new classification system for idiopathic inflammatory myopathies based on clinical manifestations and myositis-specific autoantibodies. JAMA Neurol 2018; Sep 10: E1-E10; https://doi.org/10.1001/jamaneurol.2018.2598
Pinal-Fernandez I, Casal-Dominguez M, Carrino JA, et al. Thigh muscle MRI in immune-mediated necrotising myopathy: extensive oedema, early muscle damage and role of anti-SRP autoantibodies as a marker of severity. Ann Rheum Dis 2016; 0: 1-7; http://dx.doi.org/10.1136/annrheumdis-2016-210198
Elessawy SS, Abdelsalam EM, Abdel RE, et al.Whole-body MRI for full assessment and characterization of diffuse inflammatory myopathy. Acta Radiol Open 2016; 5: 2058460116668216; https://doi.org/10.1177/2058460116668216
Huang ZG, Gao BX, Chen H, et al. An efficacy analysis of whole-body magnetic resonance imaging in the diagnosis and follow up of polymyositis and dermatomyositis. PLoSOne 2017; 12: e0181069; https://doi.org/10.1371/journal.pone.0181069
Pipitone N. Value of MRI in diagnostics and evaluation of myositis. Curr Opin Rheumatol 2016; 28: 62530; https://doi.org/10.1097/BOR.0000000000000326
Day J, Patel S, Limaye V. The role of magnetic resonance imaging techniques in evaluation and management of the idiopathic inflammatory myopathies. Semin Arthritis Rheum 2017; 46: 642-9; https://doi.org/10.1016/j.semarthrit.2016.11.001
Tomas X, Milisenda JC, Garcia-Diez AI, et al. Whole-body MRI and pathological findings in adult patients with myopathies. Skeletal Radiol 2018 Oct 30; [Epub ahead of print]; https://doi.org/10.1007/s00256-018-3107-1
Turrin M, Martinelli S. Statin-induced rhabdomyolysis: polymyositis/dermatomyositis or necrotizing autoimmune myopathy? Description of a clinical case in an elderly patient. G Ital Arterioscler 2017; 8: 83-8
Aggarwal R, Marder G, Koontz DC, et al. Efficacy and safety of adrenocorticotropic hormone gel in refractory dermatomyositis and polymoyositis. Ann Rheum Dis 2018; 77: 720-7; https://doi.org/10.1136/annrheumdis-2017-212047
Christopher-Stine L, Casciola-Rosen LA, Hong G, et al. A novel autoantibody recognizing 200-kd and 100-kd proteins is associated with an immune-mediated necrotizing myopathy. Arthritis Rheum 2010; 62: 2757-66; https://doi.org/10.1002/art.27572
Mammen AL, Chung T, Christopher-Stine A, et al. Autoantibodies against 3-hydroxy-3-metylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy. Arthritis Rheum 2011; 63: 713-21; https://doi.org/10.1002/art.30156
Noël B. Lupus erythematosus and other autoimmune diseases related to statin therapy: a systematic review. J Eur Acad Dermatol Venereol 2007; 21: 17-24; https://doi.org/10.1111/j.1468-3083.2006.01838.x
Turrin M, Martinelli S. Drug-induced lupus: simvastatin or amiodarone? A case report in elderly. Clinical Management Issues 2013; 7: 17-26; https://doi.org/10.7175/cmi.v7i1.644
Lo Schiavo A, Puca RV, Romano F, et al. Pemphigus erythematosus relapse associated with atorvastatin intake. Drug Des Devel Ther 2014; 8: 1463-5; https://doi.org/10.2147/DDDT.S66666
Alonso JJ, Jaimez L, Sabio JM, et al. Atorvastatin-induced reversible positive antinuclear antibodies. Am J Med 2002; 112: 329-30; https://doi.org/10.1016/S0002-9343(01)01102-0
Caughey GE, Gabb GM, Ronson S, et al. Association of statin exposure with histological confirmed idiopathic inflammatory myositis in an Australian population. JAMA Intern Med 2018; 178: 1224-29; https://doi.org/10.1001/jamainternmed.2018.2859
Turrin M. Statins and immune-mediated necrotizing myopathy. Clinical Management Issues 2018; 12: 77-88; https://doi.org/10.7175/cmi.v12i1.1367
Mohassel P, Mammen AL. Statin-associated autoimmune myopathy and anti-HMGCR autoantibodies. Muscle Nerve 2013; 48: 477-83; https://doi.org/10.1002/mus.23854
Lavian M, Mozaffar T, Goyal N. Clinical dermatomyositis associated with anti-HMC-CoA reductase antibody positive immuno mediated necrotizing myopathy: a case report. Neurology 2017; 88 (16 supplement): P2.125
Parikh P, Tavee J, Soltanzadeh P, et al. Anti-3-hydroxy-3-methylglutaryl-coenzyme a reductase autoantibody-positive necrotizing autoimmune myopathy with dermatomyositis-like eruption. Muscle Nerve 2018; 57: E135-E136; https://doi.org/10.1002/mus.26072
Dixit A, Abrudescu A. A case of atorvastatin-associated necrotizing autoimmune myopathy, mimicking idiopathic polymyositis. Case Rep Rheumatol 2018; 2018: 5931046; https://doi.org/10.1155/2018/5931046
Mancini GB, Tashakkor AY, Baker S, et al. Diagnosis, prevention, and management of statin adverse effects and intolerance: Canadian Working Group Consensus update. Can J Cardiol 2013; 29: 1553-68; https://doi.org/10.1016/j.cjca.2013.09.023
Nguyen KA, Li L, Lu D, et al. A comprehensive review and meta-analysis of risk factors for statin-induced myopathy. Eur J Clin Pharmacol 2018; 74: 1099-109; https://doi.org/10.1007/s00228-018-2482-9
Turrin M, Tinello A. Hypercholesterolemia, hyperCKemia and macro-creatine kinase: a case report. Intern Emerg Med 2012: 7 (Suppl 4): 361. S552-S553; https://doi.org/10.1007/s11739-012-0888-4
Casciola-Rosen L, Hall JC, Mammen Al, et al. Isolated elevation of aldolase in the serum of myositis patients: a potential biomarker of damaged early regenerating muscle cells. Clin Exp Rheumatol 2012; 30: 548-53
Poli A, Barbagallo CM, Cicero A, et al. Nutraceuticals and functional foods for the control of plasma cholesterol levels. An Intersociety position paper. Pharmacol Res 2018; 134: 51-60; https://doi.org/10.1016/j.phrs.2018.05.015
Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 2017; 376: 1713-22; https://doi.org/10.1056/NEJMoa1615664
Szarek M, White HD, Schwartz GG, et al.; ODYSSEY OUTCOMES Committees and Investigators. Alirocumab reduces total nonfatal cardiovascular and fatal events in the ODYSSEY OUTCOMES trial. J Am Coll Cardiol 2018 Oct 27. pii: S0735-1097(18)38961-7. [Epub ahead of print]; https://doi.org/10.1016/j.jacc.2018.10.039
Published
Issue
Section
License
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution Non-Commercial 4.0 Licence that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. The Publication Agreement can be downloaded here, and should be signed by the Authors and sent to the Publisher when the article has been accepted for publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
- Authors are permitted to post their work online after publication (the article must link to publisher version, in html format)